← Leaderboards
Daniel Sterman
University Of Pennsylvania
$5,215,085
Attributed
$5,215,085
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $485.9K · FY2005–21$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$5,215,085 · 8
By mechanism
P01$3,595,522 · 2
M01$1,214,034 · 5
R21$405,529 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Steven Mark Albelda$22,046,338
- Timothy C Zhu$9,831,408
- Andrew R Haas$3,721,334
- Marcelo Gabriel Kazanietz$22,841,058
- Carl H. June$35,377,952
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchGene TherapyMesotheliomaHuman SubjectHuman Therapy EvaluationClinical Trial Phase IGanciclovirTransfection /Expression VectorAdenoviridaeNeoplasm /Cancer ChemotherapyClinical TrialsIntravenous AdministrationT-LymphocyteCellsResponseTumorBaseMalignant NeoplasmsDoseImmune ResponseThymidine KinaseAdenovirusesImmuno-Gene TherapyFunding
Grant awards (35)
Bronchoscopic Cryo-Immunotherapy of Lung Cancer$184,331
R21 · FY2021 · CA · contact PI
Bronchoscopic Cryo-Immunotherapy of Lung Cancer$221,198
R21 · FY2019 · CA · contact PI
Clinical Trials in Mesothelioma$302,808
P01 · FY2016 · CA · contact PI
Clinical Trials in Mesothelioma$302,808
P01 · FY2015 · CA · contact PI
Clinical Trials in Mesothelioma$296,893
P01 · FY2014 · CA · contact PI
Clinical Trials in Mesothelioma$290,979
P01 · FY2013 · CA · contact PI
Clinical Trials in Mesothelioma$302,808
P01 · FY2012 · CA · contact PI
Clinical Trials in Mesothelioma$428,952
P01 · FY2010 · CA · contact PI
Clinical Trials in Mesothelioma$472,015
P01 · FY2009 · CA · contact PI
Clinical Trials in Mesothelioma$485,852
P01 · FY2008 · CA · contact PI
Clinical Trials in Mesothelioma$458,054
P01 · FY2007 · CA · contact PI
Clinical Trials in Mesothelioma$254,353
P01 · FY2006 · CA · contact PI
INTRAPLEURAL ADENOVIRAL-MEDIATED INTERFERON-BETA (IFN-B) GENE TRANSFER$38,177
M01 · FY2005 · RR
IFN-B Gene Transfer for Pleural Malignancies$5,681
M01 · FY2004 · RR
UPCC 5598: GENE THERAPY OF MALIGNANT MESOTHELIOMA USING EL/E4 DELETED ADENOVIRUS$124,146
M01 · FY2002 · RR
UPCC#5597:A PHASE I TRIAL OF EL/E4 DELETED AD.RSVTK VIRUS W/ GANCICLOVIR$124,146
M01 · FY2002 · RR
UPCC: TRIAL OF INTRAVENOUS PV701 IN PTS W SOLID TUMORS$124,146
M01 · FY2002 · RR
UPCC#5597:A PHASE I TRIAL OF EL/E4 DELETED AD.RSVTK VIRUS W/ GANCICLOVIR$124,146
M01 · FY2001 · RR
UPCC 5598: GENE THERAPY OF MALIGNANT MESOTHELIOMA USING EL/E4 DELETED ADENOVIRUS$124,146
M01 · FY2001 · RR
UPCC: TRIAL OF INTRAVENOUS PV701 IN PTS W SOLID TUMORS$124,146
M01 · FY2001 · RR
UPCC: TRIAL OF INTRAVENOUS PV701 IN PTS W SOLID TUMORS$0
M01 · FY2001 · RR
UPCC#5597:A PHASE I TRIAL OF EL/E4 DELETED AD.RSVTK VIRUS W/ GANCICLOVIR$0
M01 · FY2001 · RR
UPCC 5598: GENE THERAPY OF MALIGNANT MESOTHELIOMA USING EL/E4 DELETED ADENOVIRUS$0
M01 · FY2001 · RR
GENE THERAPY OF MALIGNANT MESOTHELIOMA USING E1 DELETED ADENOVIRUS$187,536
M01 · FY2000 · RR
GENE THERAPY OF MALIGNANT MESOTHELIOMA USING E1 DELETED ADENOVIRUS$187,536
M01 · FY2000 · RR
GENE THERAPY OF MALIGNANT MESOTHELIOMA USING E1 DELETED ADENOVIRUS$25,114
M01 · FY2000 · RR
UPCC#5597:A PHASE I TRIAL OF EL/E4 DELETED AD.RSVTK VIRUS W/ GANCICLOVIR$25,114
M01 · FY2000 · RR
UPCC 5598: GENE THERAPY OF MALIGNANT MESOTHELIOMA USING EL/E4 DELETED ADENOVIRUS$0
M01 · FY2000 · RR
UPCC 5598: GENE THERAPY OF MALIGNANT MESOTHELIOMA USING EL/E4 DELETED ADENOVIRUS$0
M01 · FY2000 · RR
UPCC 5598: GENE THERAPY OF MALIGNANT MESOTHELIOMA USING EL/E4 DELETED ADENOVIRUS$0
M01 · FY2000 · RR
UPCC#5597:A PHASE I TRIAL OF EL/E4 DELETED AD.RSVTK VIRUS W/ GANCICLOVIR$0
M01 · FY2000 · RR
UPCC#5597:A PHASE I TRIAL OF EL/E4 DELETED AD.RSVTK VIRUS W/ GANCICLOVIR$0
M01 · FY2000 · RR
UPCC: TRIAL OF INTRAVENOUS PV701 IN PTS W SOLID TUMORS$0
M01 · FY2000 · RR
UPCC: TRIAL OF INTRAVENOUS PV701 IN PTS W SOLID TUMORS$0
M01 · FY2000 · RR
UPCC: TRIAL OF INTRAVENOUS PV701 IN PTS W SOLID TUMORS$0
M01 · FY2000 · RR